Nonsteroidal anti-inflammatory drug use and Alzheimer’s disease: a case-control study in Rochester, Minnesota, 1980 through 1984
Abstract
Objective To compare the frequency of use of nonsteroidal anti-inflammatory drugs (NSAIDs) among 302 incident cases of Alzheimer's disease (AD) and age- and sex-matched control subjects. Design We undertook a retrospective case-control study, using the resources of the Rochester Epidemiology Project. Material and methods In ongoing studies of dementia in Rochester, Minnesota, we identified all incident cases of AD with onset between 1980 and 1984. From among all Rochester residents who received care at Mayo Clinic Rochester during those years, we selected one age- (within 3 years) and sex-matched control subject. For this study, exposure to a prescription NSAID was defined as prescribed use for 7 or more days during the 2-year window of time encompassing the year of onset and the year before onset among cases and the corresponding index year and the year prior for control subjects. Results The odds ratio (OR) for exposure, as described, to a prescription NSAID versus no exposure to any NSAID was 0.79 (95% confidence interval [CI], 0.45 to 1.38); the OR was 1.00 (95% CI, 0.52 to 1.92) for women and 0.40 (95% CI, 0.13 to 1.29) for men. Similarly, the overall OR for aspirin exposure versus no NSAID exposure was 0.90 (95% CI, 0.54 to 1.50). Conclusion These data are suggestive but not confirmatory of a protective effect of NSAIDs for AD.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Retrospective studies demonstrate that sustained NSAID treatment during mid-life significantly decreases the risk of AD.
“Second, retrospective studies demonstrate that sustained NSAID treatment during mid-life significantly decreases the risk of AD (109, 110).”
From The Inflammatory Continuum of Traumatic Brain Injury and Alzheimer’s Disease (2018) · cites this paper as [109]
Cites
Risk of Alzheimer's disease and duration of NSAID use
Stewart, W. F., Kawas, C., Corrada, M., & Metter, E. J. (1997) · Neurology · doi:10.1212/wnl.48.3.626 · Cited by 1,132 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Inflammation as a central mechanism in Alzheimer's disease
Kinney, J. W., Bemiller, S. M., Murtishaw, A. S., Leisgang, A. M., Salazar, A. M., & Lamb, B. T. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.06.014 · Cited by 2,253 · see citing works
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
in 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. B., & Stricker, B. H. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010178 · Cited by 1,196 · see citing works
Inflammation in Alzheimer Disease--A Brief Review of the Basic Science and Clinical Literature
Wyss-Coray, T., & Rogers, J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006346 · Cited by 975 · see citing works
Cyclooxygenase‐independent actions of cyclooxygenase inhibitors
Tegeder, I., Pfeilschifter, J. M., & Geißlinger, G. (2001) · The FASEB Journal · doi:10.1096/fj.01-0390rev · Cited by 748 · see citing works
Inflammatory processes in Alzheimer's disease
Heneka, M. T., & O'Banion, M. K. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.11.017 · Cited by 782 · see citing works
Etminan, M., Gill, S., & Samii, A. (2003) · BMJ · doi:10.1136/bmj.327.7407.128 · Cited by 511 · see citing works
NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies
McGeer, P. L., & McGeer, E. G. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.03.013 · Cited by 498 · see citing works
The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy
McGeer, P. L., & McGeer, E. G. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1177-7 · Cited by 467 · see citing works
Neuroinflammatory processes in Alzheimer’s disease
Heneka, M. T., O’Banion, M. K., Terwel, D., & Kummer, M. P. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0438-z · Cited by 433 · see citing works
“Epidemiological studies have suggested a beneficial effect of non-steroidal anti-inflammatory drugs (NSAIDs) in AD (Rogers et al. 1993; McGeer et al. 1996; Anthony et al. 2000; Breitner et al. 1995; Breitner 1996; Szekely et al. 2004; Stewart et al. 1997; Beard et al. 1998; In t’Veld et al. 2001).”
BackgroundNonsteroidal Anti-Inflammatory Drugs for the Prevention of Alzheimer’s Disease: A Systematic Review
Szekely, C. A., Thorne, J. E., Zandi, P. P., Ek, M., Messias, E., Breitner, J. C. S., & Goodman, S. N. (2004) · Neuroepidemiology · doi:10.1159/000078501 · Cited by 394 · see citing works
Gorelick, P. B. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05726.x · Cited by 361 · see citing works
Reduced incidence of AD with NSAID but not H2receptor antagonists
Zandi, P. P., Anthony, J. C., Hayden, K. M., Mehta, K. M., Mayer, L. S., & Breitner, J. C. S. (2002) · Neurology · doi:10.1212/wnl.59.6.880 · Cited by 314 · see citing works
Evidence for glial-mediated inflammation in aged APPSW transgenic mice
Benzing, W. C., Wujek, J. R., Ward, E. K., Shaffer, D. J., Ashe, K. H., Younkin, S. G., & Brunden, K. R. (1999) · Neurobiology of Aging · doi:10.1016/s0197-4580(99)00065-2 · Cited by 298 · see citing works
RETRACTED: Neuroinflammatory Markers: Key Indicators in the Pathology of Neurodegenerative Diseases
Rauf, A., Badoni, H., Abu-Izneid, T., Olatunde, A., Rahman, M., Painuli, S., Semwal, P., Wilairatana, P., & Mubarak, M. (2022) · Molecules · doi:10.3390/molecules27103194 · Cited by 273 · see citing works
RetractedInflammation in Alzheimer's disease: relevance to pathogenesis and therapy
Zotova, E., Nicoll, J. A. R., Kalaria, R. N., Holmes, C., & Boche, D. (2010) · Alzheimer s Research & Therapy · doi:10.1186/alzrt24 · Cited by 257 · see citing works
Wang, J., Tan, L., Wang, H.-F., Tan, C.-C., Meng, X.-F., Wang, C., Tang, S.-W., & Yu, J.-T. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-141506 · Cited by 234 · see citing works
Current Pharmacotherapy for Alzheimer's Disease
Lleó, A., Greenberg, S. M., & Growdon, J. H. (2005) · Annual Review of Medicine · doi:10.1146/annurev.med.57.121304.131442 · Cited by 346 · see citing works
The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease
Aisen, P. S. S. (2002) · The Lancet Neurology · doi:10.1016/s1474-4422(02)00133-3 · Cited by 201 · see citing works
Over-the-counter analgesics and antipyretics: A critical assessment
Hersh, E. V., Moore, P. A., & Ross, G. L. (2000) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)80043-0 · Cited by 180 · see citing works
Pasqualetti, P., Bonomini, C., Dal Forno, G., Paulon, L., Sinforiani, E., Marra, C., Zanetti, O., & Maria Rossini, P. (2009) · Aging Clinical and Experimental Research · doi:10.1007/bf03325217 · Cited by 172 · see citing works
Risk Factors for Nursing Home Placement in a Population‐Based Dementia Cohort
Smith, G. E., Kokmen, E., & O'Brien, P. C. (2000) · Journal of The American Geriatrics Society · doi:10.1111/j.1532-5415.2000.tb04998.x · Cited by 171 · see citing works
Self-citationInvolvement of Fc Receptors in Disorders of the Central Nervous System
Okun, E., Mattson, M. P., & Arumugam, T. V. (2009) · NeuroMolecular Medicine · doi:10.1007/s12017-009-8099-5 · Cited by 142 · see citing works
The Inflammatory Continuum of Traumatic Brain Injury and Alzheimer’s Disease
Kokiko-Cochran, O. N., & Godbout, J. P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00672 · Cited by 128 · see citing works
Alzheimer?s associated inflammation, potential drug targets and future therapies
Stuchbury, G., & M�nch, G. (2004) · Journal of Neural Transmission · doi:10.1007/s00702-004-0188-x · Cited by 111 · see citing works
“, 2001) and Rochester (Beard et al., 1998) studies supports the general neuroprotective nature of NSAIDs, but the variety of NSAIDs available results in conflicting clinical evidence.”
BackgroundResultInflammation in Neurological Disorders: The Thin Boundary Between Brain and Periphery
Cervellati, C., Trentini, A., Pecorelli, A., & Valacchi, G. (2020) · Antioxidants and Redox Signaling · doi:10.1089/ars.2020.8076 · Cited by 138 · see citing works
Neuronal death in Alzheimer’s disease and therapeutic opportunities
Donev, R., Kolev, M. V., Millet, B., & Thome, J. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00889.x · Cited by 124 · see citing works
Inflammatory mechanisms in neurodegeneration
Nichols, M. R., St‐Pierre, M., Wendeln, A., Makoni, N. J., Gouwens, L. K., Garrad, E. C., Sohrabi, M., Neher, J. J., Tremblay, M., & Combs, C. K. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14674 · Cited by 122 · see citing works
“…drug (NSAIDs) usage to the risk of AD development and also confirmed an inverse association between NSAID use and AD (Andersen et al. 1995; Breitner et al. 1995; Stewart et al. 1997; Beard et al. 1998; Broe et al. 2000; in ‘t Veld et al. 2001; Lindsay et al. 2002; Zandi et al. 2002).”
BackgroundDo NSAIDs prevent Alzheimer's disease? And, if so, why? The epidemiological evidence.
Zandi, P., & Breitner, J. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00297-4 · Cited by 112 · see citing works
Tan, J. R., Town, T., Mori, T., Wu, Y., Saxe, M., Crawford, F., & Mullan, M. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-20-07587.2000 · Cited by 138 · see citing works
“This suggestion is supported by clinical evidence, in which elderly persons using NSAIDs demonstrate only an ;20% reduction in risk for AD (Beard et al., 1998), and AD patients using NSAIDs have only partial amelioration of disease symptoms (Rich et al., 1995).”
BackgroundResultMeta-analysis of nonsteroidal antiinflammatory drug use and risk of dementia.
de Craen, A. D., Gussekloo, J., Vrijsen, B., & Westendorp, R. (2005) · American Journal of Epidemiology · doi:10.1093/aje/kwi029 · Cited by 111 · see citing works
Molecular targets of non-steroidal anti-inflammatory drugs in neurodegenerative diseases
Lleo, A., Galea, E., & Sastre, M. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-6516-1 · Cited by 93 · see citing works
Münch, G. W., Gasic‐Milenkovic, J., Dukić-Stefanović, S., Kuhla, B., Heinrich, K., Riederer, P. F., Huttunen, H. J., Founds, H., & Sajithlal, G. B. (2003) · Experimental Brain Research · doi:10.1007/s00221-003-1389-5 · Cited by 82 · see citing works
“Its relevance for the disease progression is also supported by epidemiological studies, which have shown a reduced risk of AD among long-term users of anti-inflammatory drugs (Beard et al. 1998; in t’ Veld et al. 2001).”
BackgroundResultTrepanier, C. H., & Milgram, N. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-090667 · Cited by 78 · see citing works
Current Therapeutic Options for Alzheimers Disease
Lleó, A. (2007) · Current Genomics · doi:10.2174/138920207783769549 · Cited by 76 · see citing works
Nonsteroidal anti-inflammatory drug use and Alzheimer's disease risk: the MIRAGE Study
Yip, A., Green, R., Huyck, M., Cupples, L., & Farrer, L. (2005) · BMC Geriatrics · doi:10.1186/1471-2318-5-2 · Cited by 78 · see citing works
“This result is consistent with those of prior studies which found a similar association despite differences in study design (cross-sectional [1,2] vs. case-control [3-6,10,11] vs. prospective [7-9,12]), sampling frame (family members [10] vs. registry-based [11] vs. general population [1- 9,12]), ascertainment of expo…”
InfluentialEvaluation of selective COX-2 inhibitors for the treatment of Alzheimer's disease.
Aisen, P. (2002) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(02)00374-3 · Cited by 74 · see citing works
Do nonsteroidal antiinflammatory drugs reduce the risk of Alzheimer's disease?
Breitner, J., & Zandi, P. (2001) · New England Journal of Medicine · doi:10.1056/nejm200111223452110 · Cited by 72 · see citing works
Apetz, N., Münch, G. W., Govindaraghavan, S., & Gyengési, E. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666140917110635 · Cited by 72 · see citing works
Therapeutic implications of the prostaglandin pathway in Alzheimer's disease
Cudaback, E., Jorstad, N. L., Yang, Y. J., Montine, T. J., & Keene, C. D. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.014 · Cited by 66 · see citing works
New Anti-inflammatory Treatment Strategy in Alzheimer’s Disease
Sugaya, K., Uz, T., Kumar, V., & Manev, H. (2000) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.82.85 · Cited by 64 · see citing works
Desplats, P., Gutierrez, A. M., Antonelli, M. C., & Frasch, M. G. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.10.013 · Cited by 70 · see citing works
NSAIDs for the Chemoprevention of Alzheimer’s Disease
Szekely, C. A., Town, T., & Zandi, P. P. (2007) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/1-4020-5688-5_11 · Cited by 52 · see citing works
Inflammation in Alzheimer’s disease
Heneka, M. T. (2006) · Clinical Neuroscience Research · doi:10.1016/j.cnr.2006.09.005 · Cited by 25 · see citing works
IL-9 alterations linked to Alzheimer’s disease in African Americans
Wharton, W., Kollhoff, A. L., Gangishetti, U., Verble, D., Upadhya, S. W., Zetterberg, H., Kumar, V., Watts, K. D., Kippels, A. J., Gearing, M., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25543 · Cited by 57 · see citing works
Landi, F., Cesari, M., Onder, G., Russo, A., Torre, S., & Bernabei, R. (2003) · The American journal of geriatric psychiatry · doi:10.1097/00019442-200303000-00008 · Cited by 55 · see citing works
Jonker, C., Comijs, H., & Smit, J. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00188-4 · Cited by 50 · see citing works
Veld, B. '. '., Launer, L., Breteler, M., Hofman, A., & Stricker, B. H. C. (2002) · Epidemiologic Reviews · doi:10.1093/epirev/mxf001 · Cited by 50 · see citing works
Indomethacin for Alzheimer's disease
Tabet, N., & Feldman, H. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003673 · Cited by 50 · see citing works
Breuer, B., Trungold, S., Martucci, C., Wallenstein, S., Likourezos, A., Libow, L., & Zumoff, B. (2001) · Maturitas · doi:10.1016/s0378-5122(01)00208-0 · Cited by 50 · see citing works
Mechanistic role of boswellic acids in Alzheimer’s disease: Emphasis on anti-inflammatory properties
Siddiqui, A., Shah, Z., Jahan, R. N., Othman, I., & Kumari, Y. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112250 · Cited by 54 · see citing works
Nagano, S., Huang, X., Moir, R. D., Payton, S. M., Tanzi, R. E., & Bush, A. I. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313003200 · Cited by 48 · see citing works
Neuropathology and treatment of Alzheimer disease: did we lose the forest for the trees?
Castellani, R. J., Zhu, X., Lee, H., Moreira, P. I., Perry, G. L., & Smith, M. A. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.5.473 · Cited by 42 · see citing works
Activation of microglia: A neuroinflammatory role for CAP37
Pereira, H., Ruan, X.-J., & Kumar, P. (2003) · Glia · doi:10.1002/glia.10167 · Cited by 42 · see citing works
“…mechanisms and the identity of the mediators involved in initiating or regulating these processes (Goldbager et al., 1989; Breitner, 1996; Beard et al., 1998; Pasinetti, 1998; Pitchumoni and Doraiswamy, 1998; Popovic et al., 1998; Schubert et al., 1998; Yermakova et al., 1999; Cole and…”
BackgroundPetegnief, V., Saura, J., DeGregorio‐Rocasolano, N., & Paul, S. M. (2001) · Neuroscience · doi:10.1016/s0306-4522(01)00046-x · Cited by 39 · see citing works
Khezri, M. R., Yousefi, K., Mahboubi, N., Hodaei, D., & Ghasemnejad‐Berenji, M. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.114945 · Cited by 41 · see citing works
Targeting innate immunity to protect and cure Alzheimer’s disease: opportunities and pitfalls
Cisbani, G., & Rivest, S. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01083-4 · Cited by 43 · see citing works
Treatments for Alzheimer Disease
Potyk, D. K. (2005) · Southern Medical Journal · doi:10.1097/01.smj.0000166671.86815.c1 · Cited by 37 · see citing works
Neuroinflammation in Alzheimer's disease and beneficial action of luteolin
Delgado, A., Cholevas, C., & Theoharides, T. C. (2021) · BioFactors · doi:10.1002/biof.1714 · Cited by 46 · see citing works
Trojan, E., Bryniarska, N., Leśkiewicz, M., Regulska, M., Chamera, K., Szuster-Głuszczak, M., Leopoldo, M., Lacivita, E., & Basta‐Kaim, A. (2019) · Current Neuropharmacology · doi:10.2174/1570159x17666191019170244 · Cited by 42 · see citing works
Prevalence of cognitive impairment in patients with rheumatoid arthritis: a cross sectional study
McDowell, B., Marr, C., Holmes, C., Edwards, C. J., Cardwell, C. R., McHenry, M., Meenagh, G., & McGuinness, B. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-04417-w · Cited by 39 · see citing works
The Link between Cutaneous Inflammation and Cognitive Impairment
Wen, S., Elias, P., Wakefield, J., Mauro, T., & Man, M.-Q. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18360 · Cited by 33 · see citing works
Current approaches to reducing gastrointestinal toxicity of low-dose aspirin.
Lanas, Á. (2001) · American Journal of Medicine · doi:10.1016/s0002-9343(00)00647-1 · Cited by 33 · see citing works
Flynn, B. L., & Theesen, K. A. (1999) · The Annals of Pharmacotherapy · doi:10.1345/aph.17093 · Cited by 32 · see citing works
Novel strategies for Alzheimer's disease treatment
Spencer, B. J., Rockenstein, E. M., Crews, L. A., Marr, R. A., & Masliah, E. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.12.1853 · Cited by 31 · see citing works
Alzheimer’s Disease Treatment: The Search for a Breakthrough
Reiss, A. B., Muhieddine, D., Jacob, B., Mesbah, M., Pinkhasov, A., Gomolin, I. H., Stecker, M. M., Wısnıewskı, T., & Leon, J. D. (2023) · Medicina · doi:10.3390/medicina59061084 · Cited by 29 · see citing works
Sedeyn, J. C., Wu, H., Hobbs, R. D., Levin, E. C., Nagele, R. G., & Venkataraman, V. (2015) · BioMed Research International · doi:10.1155/2015/937148 · Cited by 30 · see citing works
The functions of the amyloid precursor protein gene.
Panegyres, P., & Atkins, E. (2011) · Reviews in the Neurosciences · doi:10.4236/nm.2011.22018 · Cited by 28 · see citing works
“Nonsteroidal anti-inflammatory drugs influence the development of AD [71].”
BackgroundChang, C.-W., Horng, J.-T., Hsu, C.-C., & Chen, J.-M. (2016) · Journal of Diabetes Research · doi:10.1155/2016/9027484 · Cited by 27 · see citing works
Prevention strategies for Alzheimer’s disease
Gauthier, S., Wu, L.-Y., Rosa-Neto, P., & Jia, J. (2012) · Translational Neurodegeneration · doi:10.1186/2047-9158-1-13 · Cited by 27 · see citing works
Wolfson, C., Perrault, A., Moride, Y., Esdaile, J., Abenhaim, L., & Momoli, F. (2002) · Neuroepidemiology · doi:10.1159/000048621 · Cited by 27 · see citing works
Nonsteroidal Anti-Inflammatory Drug Use and the Risk for Alzheimer???s Disease
Launer, L. J. (2003) · Drugs · doi:10.2165/00003495-200363080-00001 · Cited by 69 · see citing works
Hawkey, C., & Lanas, Á. (2001) · American Journal of Medicine · doi:10.1016/s0002-9343(00)00651-3 · Cited by 26 · see citing works
Pickering, G., Eschalier, A., & Dubray, C. (2000) · Gerontology · doi:10.1159/000022166 · Cited by 26 · see citing works
Cyclooxygenase-2: a major therapeutic advance?
Emery, P. (2001) · American Journal of Medicine · doi:10.1016/s0002-9343(00)00649-5 · Cited by 25
Inflammatory processes and Alzheimer’s disease
Walsh, S. P., & Aisen, P. S. S. (2004) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.4.5.793 · Cited by 25 · see citing works
O'Hare, E., Scopes, D. I. C., Treherne, J. M., Monaghan, J., Palmer, P. M., Amijee, H., & Kim, E.-M. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-100044 · Cited by 22 · see citing works
Improved high-performance liquid chromatographic assay for nimesulide.
Jaworowicz, D., Filipowski, M. T., & Boje, K. (1999) · Journal of Chromatography B: Biomedical Sciences and Applications · doi:10.1016/s0378-4347(98)00559-3 · Cited by 21
Treatment and prevention of aspirin-induced gastroduodenal ulcers and gastrointestinal bleeding
Lanas, Á., & Ferrández, Á. (2002) · Expert Opinion on Drug Safety · doi:10.1517/14740338.1.3.245 · Cited by 20
“However, recent epidemiological data suggest that aspirin may also be effective in the prevention of different forms of gastrointestinal (GI) cancer [5-7] and Alzheimer’s disease [8].”
BackgroundIs pharmacological prevention of Alzheimer's a realistic goal?
Anthony, J. C., Breitner, J. C. S., & Zandi, P. P. (2002) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.3.4.365 · Cited by 18 · see citing works
Vasdev, N., Green, D. E., Vines, D., McLarty, K., Mccormick, P., Moran, M. D., Houle, S., Wilson, A., & Reilly, R. (2013) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2012.1196 · Cited by 19 · see citing works
Drug-related damage of the ageing gastrointestinal tract.
Sostres, C., Gargallo, C., & Lanas, Á. (2009) · Best practice & research. Clinical gastroenterology · doi:10.1016/j.bpg.2009.10.006 · Cited by 19 · see citing works
Thinking preventively about dementia: a review
Cooper, B. K. (2002) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.707 · Cited by 17 · see citing works
“A number of retrospective studies have found a lower use of anti-inflammatory drugs (NSAIDs, aspirin and H2 receptor antagonists) among persons who develop dementia than in age-sex matched controls (e.g. Beard et al., 1998; Anthony et al., 2000).”
BackgroundMedications and Diet: Protective Factors for AD?
Kawas, C. (2006) · Alzheimer Disease and Associated Disorders · doi:10.1097/00002093-200607001-00014 · Cited by 18 · see citing works
Breuer, B., Martucci, C., Wallenstein, S., Likourezos, A., Libow, L., Peterson, A., & Zumoff, B. (2002) · The American journal of geriatric psychiatry · doi:10.1097/00019442-200205000-00011 · Cited by 18 · see citing works
Rajesh, V., Mridhulmohan, M., Jayaseelan, S., Sivakumar, P., & Ganesan, V. (2018) · Neurochemical Research · doi:10.1007/s11064-018-2554-3 · Cited by 18 · see citing works
McCullagh, C. D., Craig, D. W., McIlroy, S. P., & Passmore, A. P. (2001) · Advances in Psychiatric Treatment · doi:10.1192/apt.7.1.24 · Cited by 70 · see citing works
“Several studies have reported that intake of non-steroidal anti-inflammatory drugs (NSAIDs) is negatively associated with the risk of developing Alzheimer's disease (Beard et al, 1998).”
Neuroimmune interactions in Alzheimer's disease—New frontier with old challenges?
Prokop, S., Lee, V. M. ‐., & Trojanowski, J. Q. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.10.002 · Cited by 17 · see citing works
Questions regarding future research on aspirin and the gastrointestinal tract.
Hirschowitz, B., & Hawkey, C. J. (2001) · American Journal of Medicine · doi:10.1016/s0002-9343(00)00648-3 · Cited by 12
Ongoing trials in Alzheimer’s disease
Sramek, J., & Cutler, N. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.4.899 · Cited by 12 · see citing works
Malve, H. (2017) · Indian Journal of Pharmaceutical Sciences · doi:10.4172/pharmaceutical-sciences.1000195 · Cited by 13 · see citing works
Nonsteroidal Anti-Inflammatory Drugs and Alzheimer??s Disease
Lucca, U. (1999) · CNS Drugs · doi:10.2165/00023210-199911030-00005 · Cited by 12 · see citing works
Wu, S., Rajiah, T., & Ali, A. B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262411963 · Cited by 9 · see citing works
Oxidative Stress and Protein Oxidation
Grune, T., Catalgol, B., & Jung, T. (2012) · Wiley eBooks · doi:10.1002/9781118493038.ch1 · Cited by 7 · see citing works
Vo, T., Tran, V., & Tran, V. T. L. (2021) · Journal of Research in Clinical Medicine · doi:10.34172/jrcm.2021.032 · Cited by 7 · see citing works
Ibuprofen in Prevention of Neurodegenerative Diseases
Rainsford, K. D. (2015) · doi:10.1002/9781118743614.ch14 · Cited by 2 · see citing works
Could routine vaccinations prevent dementia?
Poynton-Smith, E., Orrell, M., Morley, J., & Scherrer, J. F. (2023) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5978 · Cited by 3 · see citing works
Non-Steroidal Anti-Inflammatory Drug Use and Essential Tremor
Pan, J., Michalec, M., & Louis, E. (2014) · Neuroepidemiology · doi:10.1159/000366424 · Cited by 3 · see citing works
Aging and Cognitive Decline: Neuroprotective Strategies
do Couto, F. S., & de Mendonça, A. (2007) · Springer eBooks · doi:10.1007/978-0-387-70830-0_11 · Cited by 1 · see citing works
“However, some studies showed a nonsignificant trend toward a reduced risk for AD in people taking NSAIDs (Beard et al., 1998; Cornelius et al., 1998) and, in a stratified analysis, the results favored NSAIDs (Cornelius et al., 2004).”
ResultOsteoarthritis and APOE4 Interact to Influence Memory Decline in Non-Demented Older People
Zhou, K., Wu, P., & Initiative, A. D. N. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220138 · Cited by 1 · see citing works
VI. Other Types of Cerebrovascular Disorders
Shinohara, Y., Yanagihara, T., Abe, K., Yoshimine, T., Fujinaka, T., Chuma, T., Ochi, F., Nagayama, M., Ogawa, A., Suzuki, N., et al. (2011) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2011.05.013
- Authors
- Beard, C. M., Waring, S. C., O'Brien, P. C., Kurland, L. T., & Kokmen, E.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Kokmen, Emre
- ORCID
- Waring, Stephen C.
- Venue
- Mayo Clinic Proceedings
- Publisher
- Elsevier BV
- Published
- 1998-10
- Volume
- 73
- Issue
- 10
- Pages
- 951-955
- ISSN
- 0025-6196 (ISSN-L)
- OpenAlex
- W2003362379
- Cited by
- 114
- References
- 0
- Citations by year
- 2025: 2 · 2024: 1 · 2023: 2 · 2022: 5 · 2021: 3 · 2020: 3 · 2019: 5 · 2018: 3 · 2017: 1 · 2016: 1 · 2015: 2 · 2014: 3 · 2013: 2 · 2012: 2
- FWCI
- 5.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Mayo Clinic Proceedings (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (AG-06786, U01AG006786)
- National Institute of Neurological Disorders and Stroke (NS17750)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR030582, AR30582)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology › Inflammatory mediators and NSAID effects
- Keywords
- nonsteroidal anti-inflammatory drugs, Alzheimer's disease, aspirin, drug use, dementia, protective effect, sex differences, Rochester Epidemiology Project
- MeSH terms
- Aged, Alzheimer Disease, Anti-Inflammatory Agents, Non-Steroidal, Data Interpretation, Statistical, Female, Humans, Male, Retrospective Studies, Logistic Models, Odds Ratio, Case-Control Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
